Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.

Sponsor
Uzi Milman (Other)
Overall Status
Terminated
CT.gov ID
NCT02289287
Collaborator
University of Haifa (Other)
60
1
2
29.1
2.1

Study Details

Study Description

Brief Summary

Stroke is defined as a sudden vascular accident that causes brain damage and neurological impairment. Literature shows that a stroke has a negative effect on participation. Self-Management (SM) is defined as health promotion and education programs used mostly for people with chronic diseases, which aim at helping patients to maintain a feeling of wellness. The primary aim of this study is to assess the effectiveness of a group-based SM program for post-stroke patients in a community setting, and its contribution to improving participation, compared to standard care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Self-Management group-intervention
  • Behavioral: Standard Care
N/A

Detailed Description

At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up measures will be performed within a week after the end of the intervention, and 6 months thereafter, in order to examine long term effectiveness. Outcome measures are questionnaires; change will be assessed by the difference in total score between T1 |(pre-intervention), T2 (post-intervention) and T3 (after 6 months)

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.
Actual Study Start Date :
Apr 17, 2017
Actual Primary Completion Date :
Sep 19, 2019
Actual Study Completion Date :
Sep 19, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Self-Management group-intervention

Participants will receive Self-Management group-intervention + Standard Care

Behavioral: Self-Management group-intervention
At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.

Active Comparator: Standard Care

Participants will receive Standard Care only

Behavioral: Standard Care
At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.

Outcome Measures

Primary Outcome Measures

  1. Patient Participation [12 and 36 weeks]

    The primary outcome measure is the change in patient's participation, as defined by the International Classification of Function, Disability and Health (ICF), between the three assessment points - baseline, 12 and 36 weeks.

Secondary Outcome Measures

  1. Self-efficacy for self-management behaviors. [12 and 36 weeks]

    Self-efficacy for self-management behaviors.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Cerebrovascular accident diagnosed 3-18 months before enrollment. Treated at th Neurologic Rehabilitation Center of Clalit Health Services in Kiryat Byalik, Israel.

Living in the community (in their homes). Are capable of basic communication in Hebrew.

Exclusion Criteria:

Moderate-severe stroke (National Institutes of Health Stroke Scale (NIHSS) score ≤ 16).

Moderate-Severe Cognitive impairment (Montreal Cognitive Assessment (MOCA) - total score ≤ 16). Inability to provide informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel

Sponsors and Collaborators

  • Uzi Milman
  • University of Haifa

Investigators

  • Principal Investigator: Tamar Adar, MD, Clinical Research Unit, Clalit Health Services, Haifa District, HAIFA, ISRAEL
  • Study Chair: Eli Carmeli, PhD, Department of Physical Therapy, Faculty of Social Well fare and Health Sciences, Haifa University, Haifa, Israel.
  • Principal Investigator: Hagit Harel-Katz, MSc, Clinical Research Unit, Clalit Health Services, Haifa District, HAIFA, ISRAEL
  • Study Director: Uzi Milman, MD, Clinical Research Unit, Clalit Health Services, Haifa District, HAIFA, ISRAEL

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Uzi Milman, Director, Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District and the Department of Family Medicine, Faculty of Medicine, Technion- Israel Institute of Technology, HAIFA, ISRAEL, Clalit Health Services
ClinicalTrials.gov Identifier:
NCT02289287
Other Study ID Numbers:
  • COM - 0018-14-CTIL
First Posted:
Nov 13, 2014
Last Update Posted:
Sep 20, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Uzi Milman, Director, Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District and the Department of Family Medicine, Faculty of Medicine, Technion- Israel Institute of Technology, HAIFA, ISRAEL, Clalit Health Services
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 20, 2019